在生命科学探索的最前沿，合成生物学以其独特的创新潜力和广泛的应用前景，成为全球投资者关注的焦点。目前，中国的合成生物学市场正处于一个爆发的转折点 上。据统计，中国合成生物学共116家上市企业，涵盖了技术平台供应商、提供生物合成解决方案的CXO企业，以及谋求转型的化工与医药企业。 在这片赛场上，有深耕行业38载、拥有国资背景的老将（安琪酵母），也有成立于2023年的新兴玩家。这一幅由中国企业创造的绘卷上，不仅展现了糖、蛋 白、酶、微生物、多肽药物、AI平台等领域的累累硕果，也窥见了合成生物产业背后巨大的发展潜力与想象空间。 合成生物使能技术型企业正处于高速成长期，依托于基因编辑、基因合成、基因测序及大数据与机器学习等前沿技术，为企业提供了强大的技术支持。 然而，使能技术目前仍处于初期阶段，技术壁垒较高。因此，企业多选择与高校、科研机构、企业之间多方合作的方式推进研发进程。 | 图片来源：摩熵咨询《2024年中国合成生物学创投市场分析报告》 | | --- | 在中国合成生物学使能技术型企业中，华大智造和贝瑞和康无疑是佼佼者。 中国合成生物学使能技术型企业——华大智造 华大智造自上市以来备受关注，其业务聚焦基因测 ...

金融界5月12日消息，上证指数高开高走，中证港股通医疗主题指数 (港股通医疗主题，932069)上涨 0.59%，报787.2点，成交额163.51亿元。 数据统计显示，中证港股通医疗主题指数近一个月上涨14.60%，近三个月上涨10.23%，年至今上涨 17.07%。 据了解，中证港股通医疗主题指数从港股通证券范围内选取50只业务涉及医疗器械、医疗商业与服务、 制药与生物科技服务等领域的上市公司证券作为指数样本，以反映港股通内医疗领域上市公司证券的整 体表现。该指数以2018年12月31日为基日，以1000.0点为基点。 从中证港股通医疗主题指数持仓样本的行业来看，医疗商业与服务占比34.97%、制药与生物科技服务 占比31.72%、医疗器械占比12.28%、化学药占比10.50%、生物药品占比10.12%、中药占比0.42%。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一个定期 调整日前，权重因子一般固定不变。特殊情况下将对指数进行临时调整。当样本退市时，将其从指数样 本中 ...

Group 1 - The company, King’s Ray Biotechnology, announced a share transfer agreement to acquire 300 million shares of Probio Cayman Class A preferred shares for approximately $225 million (around HKD 1.7 billion) [1] - Following the transaction, the company's direct and indirect ownership in Probio Cayman will increase from 71.72% to 85.09% [1] - Probio Cayman will continue to be an indirect non-wholly owned subsidiary of the company after the completion of the transaction [1] Group 2 - Probio Cayman and its subsidiaries provide comprehensive Contract Development and Manufacturing Organization (CDMO) services in the biotechnology and pharmaceutical sectors, including antibody drug discovery and clinical development [2] - The company has established Probio Cayman as a leading CDMO service provider, empowering innovators in antibody development, protein therapy, cell therapy, and gene therapy [2] - Probio Cayman is expected to generate cash inflows from a licensing agreement with Lixin Pharmaceutical Technology Co., Ltd. regarding the PD-1 VHH antibody, which will further enhance its future development prospects [2]

Core Insights - The global and US innovative drug VC&PE financing amounts are expected to grow by 1.93% and 5.29% respectively in 2024, indicating a recovery in the innovative drug financing environment [1] - The demand for research and development in fields such as peptides and ADCs is strong, leading to an increase in outsourcing needs in these areas [1][2] Macro Perspective - The global innovative drug financing environment is recovering, with significant growth in the demand for innovative research in specific fields like peptides and ADCs, which is expected to enhance the CXO industry's outlook [1] - According to Crunchbase, the VC&PE financing for innovative drugs in 2024 shows positive growth, marking an improvement in the financing environment [1] Micro Perspective - CXO listed companies are seeing a recovery in new orders, with many companies like WuXi AppTec, WuXi Biologics, and others reporting a year-on-year increase of over 20% in new orders [3] - The production capacity of domestic CXO companies is mature, ensuring timely delivery of orders, which is expected to lead to double-digit revenue growth for several companies in 2025 [3] Target Companies - Recommended companies to watch include WuXi AppTec (603259.SH, 02359), WuXi Biologics (02269), WuXi AppTec (02268), Kelun Pharmaceutical (002821.SZ, 06821), and others [4]

4月27日，副省长方伟赴镇江检查安全生产工作。省政府副秘书长徐华勤参加检查。市委常委、常 务副市长张克陪同检查。 在江苏金斯瑞生物科技有限公司，方伟深入企业生产和研发一线，详细了解企业安全管理体系建设 和安全生产责任制落实情况。得知企业建立了EHS基本安全准则，成立了安全生产委员会，配备专职安 全管理机构EHS部门，方伟给予肯定。他指出，生物科技行业技术密集、工艺复杂，安全风险点多、管 理要求高，企业必须树牢底线思维，强化安全管理，持续完善安全生产各项制度，提升本质安全水平， 切实将安全责任落实到每一个岗位、每一名员工。 随后，方伟来到镇江信缘康米山颐养院，实地检查消防控制室、消防设施设备运行状况以及疏散通 道设置情况，仔细询问火灾防控、应急预案制定、日常巡查制度和员工安全培训等工作落实情况。在认 真听取养老机构负责人介绍后，方伟指出，养老机构入住人员多为高龄老人，行动不便、应急反应能力 弱，消防安全责任重大。要深刻吸取近期各地火灾事故教训，进一步压实安全管理责任，全面开展风险 隐患排查整治，完善应急处置预案，加强员工技能培训和演练，做到早发现、早处置，确保遇到突发情 况能够及时组织有效应对，切实守护入住老人 ...

Group 1 - The core index, the CESHKB, closed flat with a trading volume of 0.0 billion, reflecting a recent decline of 6.54% over the past month, but an increase of 26.60% over the last three months and a year-to-date rise of 21.09% [1] - The CESHKB index is compiled by China Securities Index Co., Ltd. under the commission of China Securities Trading Service Co., Ltd., aiming to reflect the overall performance of biotechnology companies listed in Hong Kong [1] - The base date for the index is December 12, 2014, with a base point of 2000.0 [1] Group 2 - The top ten holdings of the CESHKB index include: CanSino Biologics (11.12%), Innovent Biologics (10.75%), BeiGene (10.09%), WuXi Biologics (9.6%), China National Pharmaceutical Group (9.38%), Zai Lab (5.61%), 3SBio (5.2%), WuXi AppTec (4.56%), Kelun-Biotech (4.25%), and Genscript Biotech (3.54%) [1] - The index's holdings are entirely composed of companies listed on the Hong Kong Stock Exchange, with the biotechnology sector representing 60.67%, pharmaceutical and biotechnology services at 22.64%, chemical drugs at 13.14%, and medical devices at 3.55% [2]

Company Overview - The company operates in over 100 countries and regions, with a professional team of approximately 5,568 members as of December 31, 2024[8]. - The company serves over 225,100 customers from more than 100 countries, impacting various fields such as vaccine development and diagnostics[94]. - The company was established as an exempted limited company in the Cayman Islands on May 21, 2015, and its shares were listed on the main board of the Stock Exchange on December 30, 2015[145]. Financial Performance - The group's revenue from continuing operations for the reporting period was approximately $594.5 million, representing a 6.1% increase from approximately $560.5 million in the previous year[17]. - The adjusted net profit for the group during the reporting period was approximately $59.8 million, an increase of 2.9% compared to approximately $58.1 million in the previous period[16]. - The gross profit for the group during the reporting period was approximately $272.1 million, remaining stable compared to the previous period[17]. - The group reported a profit of approximately $2.9 billion during the reporting period, compared to a loss of approximately $355.1 million in the previous period[17]. - The revenue from the cell therapy business contributed approximately $3.2 billion, significantly boosting the group's profit growth during the reporting period[16]. - The total assets of the group increased to approximately $4.32 billion in the fiscal year 2024, up from $2.04 billion in the previous year[19]. - The cash and cash equivalents decreased to approximately $131.99 million in fiscal year 2024, down from $1.45 billion in the previous year[19]. - The company achieved a profit attributable to owners of approximately $3 billion, compared to a loss of $95.5 million in the previous period[32]. Revenue Breakdown - Revenue from the United States, Mainland China, Europe, Asia-Pacific (excluding Mainland China), and other regions for the year ended December 31, 2024, was approximately $265.1 million, $176.9 million, $80.9 million, $53.1 million, and $18.5 million, respectively, accounting for 44.6%, 29.8%, 13.6%, 8.9%, and 3.1% of total revenue[10]. - External revenue from life sciences services and products accounted for 75.8% of total revenue, while biopharmaceutical development services and industrial synthetic biology products contributed 14.8% and 9.0%, respectively[32]. - Life Sciences segment revenue reached approximately $454.9 million, a 10.2% increase from $412.9 million in the previous year[35]. - The TurboCHO® cell expression platform saw over 100% sales growth compared to the previous year[20]. Operational Highlights - The life sciences services and products platform continues to provide stable revenue, covering gene synthesis, oligonucleotide synthesis, peptide synthesis, protein production, antibody development, and life science equipment and consumables[4]. - The CDMO platform, known as Probio, empowers global biopharmaceutical innovation by providing seamless end-to-end solutions, enhancing project success rates and reducing development time[8]. - The industrial synthetic products platform, known as Basij, utilizes advanced protein engineering technology to develop products for the feed, food, grain processing, and household care industries[9]. - The company aims to optimize operational processes and enhance quality and delivery times to improve competitiveness[7]. - The company is focused on establishing strategic collaborations with business partners to build a healthy biotechnology ecosystem[7]. Investments and R&D - The company has made significant investments in cell therapy, which is expected to bring long-term value to the company and its shareholders[7]. - The company has made significant investments in R&D and talent development, which may not yield immediate profit growth but are expected to create long-term value[21]. - The company plans to invest in R&D for antibody drug development and AI drug development to accelerate innovation[36]. - The company is focused on enzyme product business growth through innovation and process optimization[42]. Employee and Management Structure - As of December 31, 2024, the total number of employees in the group is 5,568, with 53.6% in production, 11.2% in sales and marketing, 13.2% in administration, 8.8% in R&D, and 13.2% in management[102]. - The company has implemented continuous education and training programs for employees to enhance their skills and knowledge[102]. - The board of directors currently consists of 12 members, including 4 executive directors, 1 non-executive director, and 7 independent non-executive directors[105]. Strategic Initiatives - The company plans to expand its market penetration in North America and Europe by acquiring new customers in advanced therapy fields[39]. - The company is focused on expanding its product portfolio and enhancing operational efficiency through digital transformation and lean management[96]. - The company is actively pursuing new strategies in market expansion and product development to enhance its competitive position[124]. - The company aims to strengthen its position in the life sciences sector through strategic partnerships and investments in innovative technologies[125]. Governance and Compliance - The company has established a robust governance structure with various committees, including audit and compensation committees, to oversee operations[119]. - The company has adopted various share option and restricted share award plans to incentivize employees and selected participants for their contributions[101]. - The board's composition aims to improve oversight in areas such as data security and geopolitical resilience, aligning with current market trends[132]. Shareholder Information - The board of directors did not recommend the distribution of a final dividend for the year ending December 31, 2024, to retain resources for business development[148]. - The company has not reported any distributable reserves as of December 31, 2024[155]. - The company has authorized a maximum of 212,768,651 shares for issuance under the share option and incentive plans, representing 10% of the total shares issued as of the 2024 annual general meeting date[171].

Investment Rating - The report does not specify a clear investment rating for the company [1]. Core Views - Kingsray Biotechnology (1548.HK) reported a significant profit increase, with net profit reaching $2.961 billion in 2024, primarily due to the gain from the demerger of its cell therapy business [7][8]. - The company’s revenue for 2024 was $594.49 million, reflecting a 29.19% decline, but is expected to rebound with a projected revenue of $937.21 million in 2025, representing a 57.65% growth [2][9]. - The life sciences segment showed steady growth, with external revenue of approximately $450 million in 2024, up 10.2%, driven by platform upgrades and operational efficiency improvements [7][8]. Financial Summary - **Revenue Forecast**: Expected revenues for 2025, 2026, and 2027 are $937.21 million, $829.90 million, and $981.93 million respectively [2][9]. - **Net Profit Forecast**: Projected net profits for the same years are $309.95 million, $130.72 million, and $208.01 million [2][9]. - **Earnings Per Share (EPS)**: EPS is expected to decline from $1.37 in 2024 to $0.14 in 2025, before recovering to $0.10 in 2027 [2][9]. - **Return on Equity (ROE)**: ROE is projected to decrease significantly from 68.54% in 2024 to 6.69% in 2025, before gradually increasing to 4.19% in 2027 [2][9]. Business Segments - **Life Sciences Services and Products**: Revenue is expected to grow at rates of 15%, 20%, and 20% from 2025 to 2027, with stable pricing and improving gross margins [8][9]. - **Biologics Development Services**: Anticipated revenue growth of 20% in 2025, followed by 10% in the subsequent years, with a focus on expanding market penetration in North America and Europe [8][9]. - **Industrial Synthetic Biology Products**: Expected to see revenue growth of 25% in 2025, driven by new product launches and a focus on large clients [8][9].

Investment Rating - The report does not specify a clear investment rating for the company [1]. Core Insights - The company reported a significant profit increase, with net profit reaching $2.961 billion in 2024, primarily due to the gain from the demerger of its cell therapy business [7][8]. - The revenue for 2024 was $594.49 million, reflecting a decrease of 29.19% year-on-year, but is expected to rebound with a projected revenue of $937.21 million in 2025, representing a growth of 57.65% [2][8]. - The company is focusing on enhancing its life sciences services and products, with a projected revenue growth of 15% to 20% from 2025 to 2027 [8]. Financial Performance Summary - **Revenue**: - 2024: $594.49 million - 2025E: $937.21 million (growth of 57.65%) - 2026E: $829.90 million (decline of 11.45%) - 2027E: $981.93 million (growth of 18.32%) [2][9] - **Net Profit**: - 2024: $2.961 billion - 2025E: $309.95 million (decline of 89.54%) - 2026E: $130.72 million (decline of 57.82%) - 2027E: $208.01 million (growth of 59.12%) [2][9] - **Earnings Per Share (EPS)**: - 2024: $1.37 - 2025E: $0.14 - 2026E: $0.06 - 2027E: $0.10 [2][9] - **Return on Equity (ROE)**: - 2024: 68.54% - 2025E: 6.69% - 2026E: 2.75% - 2027E: 4.19% [2][9] Business Segment Performance - **Life Sciences Services and Products**: - 2024 revenue: $455 million (growth of 16%) - Expected to maintain stable pricing with projected growth rates of 15% to 20% from 2025 to 2027 [8][9]. - **Biologics Development Services**: - 2024 revenue: $95 million (decline of 13.2%) - Expected to recover with growth rates of 20% in 2025 and 10% in subsequent years [8][9]. - **Industrial Synthetic Biology Products**: - 2024 revenue: $53.7 million (growth of 25%) - Projected growth rates of 25% in 2025 and 18% in the following years [8][9]. Strategic Development - The company aims to invest in R&D for antibody drug development and AI drug development, enhancing operational efficiency and expanding global production capacity [7][8]. - It plans to strengthen its market presence in North America and Europe, focusing on customer relationships and expanding production capacity [7][8].

Investment Rating - The report does not specify a clear investment rating for the company [1] Core Views - Kingsray Biotechnology (1548.HK) reported a significant profit increase, with net profit reaching $2.961 billion in 2024, primarily due to the gain from the demerger of its cell therapy business [7][8] - The company’s revenue for 2024 was $594.49 million, reflecting a decrease of 29.19% year-on-year, but is expected to rebound with a projected revenue of $937.21 million in 2025, representing a growth of 57.65% [2][8] - The life sciences segment showed steady growth, with external revenue of approximately $450 million in 2024, up 10.2% year-on-year, driven by platform upgrades and operational efficiency improvements [7][8] Summary by Sections Financial Performance - In 2024, the company achieved a gross profit of $270 million, with a gross margin of 45.77% [10] - The projected net profit for 2025 is $309.95 million, with a significant drop in profitability expected in 2026 [2][8] - The earnings per share (EPS) for 2024 was $1.37, but is expected to decline to $0.14 in 2025 [2][8] Revenue Breakdown - Life Sciences Services and Products: Expected revenue growth of 15% in 2025, reaching $523.2 million [9] - Biologics Development Services: Anticipated revenue of $114 million in 2025, with a recovery expected after a decline in 2024 [9] - Industrial Synthetic Biology Products: Projected revenue growth of 25% in 2025, reaching $65 million [9] Strategic Development - The company plans to invest in R&D for antibody drug development and AI drug development, aiming to enhance product reliability and cost-effectiveness [7][8] - Expansion of production capacity in North America and Europe is a key focus to meet customer demands and mitigate supply chain risks [7][8] Market Position - The company’s market capitalization is approximately $27.69 billion, with a 52-week price range of HKD 8.23 to HKD 16.74 [5] - The stock has shown a relative performance against the Hang Seng Index, with fluctuations noted over the past year [4]